Clinical trials
PSMA Positive Tumors or Tumor Tissues clinical trials
Below are recruiting psma positive tumors or tumor tissues clinical trials, each written for real people, not researchers. We’re tracking 1,319 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06658951Recruiting
HER2-targeted CAR-T cell therapy for advanced solid tumors
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack cancer cells that have a high amount of a protein called HER2. It is for people with advanced solid tumors (like certain breast, stomach, or lung cancers) that have not responded to standard treatments.
Zhengzhou, HenanAges 18–70 - NCT06501183RecruitingPhase 1
Immune cell therapy for CDH17-positive advanced solid tumors
This trial tests a new treatment called anti-CDH17 CAR-T cells for people with advanced solid tumors that are CDH17-positive. The therapy uses your own immune cells, modified to target and destroy cancer cells, and aims to help when other treatments have stopped working.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07010523Recruiting
CAR-T cell therapy for MSLN positive advanced solid tumors
This trial tests a therapy using your own immune cells (T cells) modified to target mesothelin (MSLN), a protein found on some cancer cells. It may help people with certain advanced solid tumors that have not responded to or can't tolerate standard treatments.
HangzhouAges 18–75 - NCT05423977Enrolling by invitationPhase 1
Testing ZV0203 for HER2-positive advanced solid tumors
This Phase 1 study tests ZV0203, a new investigational treatment, in people with HER2-positive advanced or metastatic solid tumors that cannot be removed and have not responded to standard treatment. The goal is to find a safe dose and see how the disease responds.
Zigong, ShandongAges 18 years+ - NCT04774718RecruitingPhase 1/Phase 2
Alectinib for ALK-fusion tumors in children and teens
This trial tests how safe alectinib is and how it works in children and teens with solid tumors or brain (CNS) tumors that have an ALK gene fusion. It’s for tumors that have come back, worsened, or don’t have a good standard treatment.
Palo Alto, CaliforniaAges Up to 17 years - NCT05468970Recruiting
Study of bone and soft tissue tumors and treatment outcomes
This study looks at people with bone or soft tissue tumors to understand their features, treatments used, and survival outcomes. It may help doctors learn which care approaches work best for different tumor subtypes.
Zhengzhou, HenanAges 6–99 - NCT05523947RecruitingPhase 1/Phase 2
Study drug for HER2-positive solid tumors, with dose changes
This early-stage study tests YH32367, a drug for people whose cancer is HER2-positive. It aims to find a safe dose and see whether it can shrink HER2-positive cancers that have spread or are hard to treat.
Boston, MassachusettsAges 18 years+ - NCT06171282RecruitingEarly Phase 1
Virus therapy for advanced bone and soft tissue tumors
This trial tests an investigational virus therapy (R130) injected directly into tumors for people with advanced bone or soft tissue cancer who have exhausted standard treatments or choose not to pursue them.
ShanghaiAges 16–75 - NCT06474676RecruitingPhase 1
Modified immune cell therapy for advanced sarcoma
This trial tests a new treatment using your own immune cells (TILs) that have been modified to attack sarcoma tumors. It is for people with advanced soft tissue or bone sarcoma who have already tried at least one other therapy.
Houston, TexasAges 12 years+ - NCT06575452Recruiting
Using RNA modifications to diagnose and treat gliomas
This trial studies whether changes in RNA (the instructions inside cells) can help doctors better diagnose and treat gliomas, a type of brain tumor. If you are scheduled for surgery to remove a suspected glioma and have not had prior treatment, you may be able to join.
Montpellier, HéraultAges 18 years+ - NCT06849986RecruitingPhase 2
Immunotherapy & AI for first-line soft tissue sarcoma
This trial tests a combination of immunotherapy (a treatment that helps your immune system attack cancer) and artificial intelligence (AI) technology as the first treatment for certain types of advanced soft tissue sarcoma. It aims to see if this approach can shrink tumors or stop them from growing better than current options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT01789229Recruiting
Tumor and inflammation sample bank for one specific condition
This study builds a secure “tumor sample bank” using tissue collected from people who currently have one diagnosed condition, either cancer (malignant disease) or an ongoing inflammatory condition. Your samples could help researchers study your disease and develop better treatments in the future.
ViennaAges 18 years+ - NCT04897321RecruitingPhase 1
CAR T therapy for children with B7-H3 solid tumors
This early-phase study tests a lab-made immune therapy (CAR T cells) made from your own cells to treat children’s solid tumors that have a specific marker called B7-H3. It is designed for kids whose cancer has come back or did not respond to standard treatment, aiming to shrink tumors and keep the therapy safe.
Memphis, TennesseeAges Up to 21 years - NCT06841419Recruiting
Rebuilding soft tissue with a thigh flap
This trial uses a flap of skin and muscle from your thigh to cover wounds on the hip, thigh, or lower belly that can't be stitched closed. It may help if you have a clean wound needing reconstruction.
SohagAges Any age - NCT03911388RecruitingPhase 1
HSV G207 for Children with Recurrent Cerebellar Brain Tumors
This trial is testing a virus called HSV G207, which is injected directly into the tumor, to treat children and young adults with a type of brain tumor in the cerebellum that has come back or not responded to standard treatments.
Birmingham, AlabamaAges 3–22 - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Little Rock, ArkansasAges 18 years+ - NCT06600802Recruiting
Lu-PSMA treatment for advanced prostate cancer
This study tests a radioactive drug called Lu-PSMA-617 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly to the tumor.
Clermont-FerrandAges 18 years+ - NCT06912152RecruitingPhase 1
Testing MT027 for advanced belly-lining cancers
This trial tests an experimental intraperitoneal therapy (MT027) for people whose advanced solid tumors have spread to the lining of the belly (peritoneum) and haven't responded to standard treatments. It aims to see if this new approach can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–70 - NCT05890781Recruiting
Study pediatric cancer using lab-made immune organoids
This trial uses special lab models (“immune organoids”) to study certain cancers in children and young people. It may help researchers learn what those cancers do and improve future treatment ideas.
VillejuifAges Up to 25 years - NCT07062003Recruiting
Minibeam radiation for skin or soft tissue tumors
This trial tests a new type of radiation called minibeam therapy for people with skin or soft tissue cancers that have come back or spread. It's designed to help shrink tumors that standard treatments haven't worked well for, and it uses a special device to focus the radiation more precisely.
Rochester, MinnesotaAges 18 years+ - NCT02146170Recruiting
Blood and tissue collection study for several lung and chest cancers
This study collects tissue (and follows patients over time) to better understand the natural course of several types of chest cancers. It may help researchers learn which tests and treatments work best in different cancer types.
Bethesda, MarylandAges 18 years+ - NCT07470008Recruiting
Registry study for histotripsy in adults with soft tissue tumors
This study is a registry for adults getting histotripsy—a non-invasive ultrasound that breaks down soft tissue tumors—at UCSF. Joining means researchers can follow your treatment and outcomes to learn more about how well histotripsy works.
San Francisco, CaliforniaAges 18 years+ - NCT06861244RecruitingPhase 2
ETMR brain tumor trial for children
This trial is for children with a rare brain tumor (ETMR) who have not had radiation. Depending on how much tumor is left after surgery and if it has spread, the study compares giving radiation early versus high-dose chemotherapy.
Birmingham, AlabamaAges Any age - NCT00900471Recruiting
Store tissue samples from surgery for suspected solid tumors
This study collects and stores small tissue samples from people who have surgery or a biopsy for a suspected solid (non-blood) tumor. It helps researchers study these cancers for future testing and research.
Winston-Salem, North CarolinaAges 18–120
Hear when a new PSMA Positive Tumors or Tumor Tissues trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psma positive tumors or tumor tissues?
- Yes. Clin2 currently lists 1,319 recruiting psma positive tumors or tumor tissues studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psma positive tumors or tumor tissues trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psma positive tumors or tumor tissues trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.